Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide
Barenbaum SR, Gonzalez A, Verzani Z, Zhao AS, Shukla AP
Summary
This real-world study of 293 patients found that tirzepatide produced 10.3% total body weight loss in non-weight-reduced patients versus 7.2% in those who had already lost ≥10% body weight before starting tirzepatide. Among patients who switched from semaglutide due to plateau, tirzepatide achieved 8.1% additional weight loss versus only 2.9% for true non-responders.
Clinical Significance
This study provides critical real-world data on tirzepatide's effectiveness in patients who have already undergone significant weight loss or failed semaglutide — two increasingly common clinical scenarios. The 8.1% weight loss for semaglutide plateau patients supports tirzepatide as an effective second-line option.
Key Findings
- Overall: 293 patients, 65% female, mean BMI 36.15 kg/m²
- Weight-reduced vs. naive: 7.2% vs. 10.3% TBW loss (p<0.001)
- Semaglutide switchers: 61 patients switched from semaglutide
- Plateau patients: 8.1% TBW loss on tirzepatide
- Non-responders: 2.9% TBW loss (p<0.001)
- T2D impact: Weight-reduced status effect remained significant among non-T2D patients
Clinical Implications
For clinicians managing patients on semaglutide who plateau or don't respond, this data supports switching to tirzepatide — particularly for patients who achieved initial weight loss but hit a plateau. True non-responders to semaglutide had modest additional benefit from tirzepatide, suggesting some degree of cross-resistance.
Verwandte Forschung
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…
Tirzepatide/Semaglutide Weight Loss Intervention in Patients With Endometrial Cancer and Obesity
Memorial Sloan Kettering is conducting a pilot study evaluating tirzepatide (with semaglutide as alt…
Pilot Weight Loss Intervention With Dual GIP/GLP-1 Receptor Agonist Therapy in Patients With Endometrial Cancer and Obesity
Memorial Sloan Kettering is conducting a pilot study evaluating weekly subcutaneous tirzepatide (2.5…
Exposure-Adjusted Safety and Efficacy of GLP-1 and GLP-1/GIP Receptor Agonists for Weight Management and Type 2 Diabetes
This comprehensive analysis of FDA regulatory data across 14 medications and over 34,000 safety subj…